Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cav1.3 Inhibitor Pilot in Primary Aldosteronism
NCT05686993Completed
- Sponsor
- Queen Mary University of London
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cinnarizine in primary aldosteronism (PA), sponsored by Queen Mary University of London. Primary endpoint: Aldosterone change at 6 weeks. Started Apr 2023; status: completed.
02
Drugs
cinnarizine
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT05686993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686993.